Pierre Meulien was most recently the Executive Director of the Innovative Medicines Initiative and oversaw its transition to the Innovative Health Initiative, a €2.4 billion cross-sector initiative in the health innovation ecosystem in Europe. He is now an independent consultant in biomedical R&I.

Previously, Dr Meulien was President and CEO of Genome Canada (2010-15) and was Chief Scientific Officer for Genome British Columbia. He has also served as founding CEO of the Dublin Molecular Medicine Centre and worked in the private sector with the French biotechnology company Transgene, and with Aventis Pasteur (now Sanofi Pasteur) as Director of Research at the Marcy l’Etoile (France) facility and then Senior Vice President for R&D at the Willowdale site (Ontario).